News Releases

Month Year

Nov 9, 2016

RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259

Patient Data Expected in Q4 2017

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that...
Nov 2, 2016

RegeneRx Receives Notice of Allowance for Patent for Tβ4 Eye Drop Formulation

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Sep 30, 2016

RegeneRx Joint Venture Initiates Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome

Patient Enrollment to Begin in Q4 With Data Readout in H2 2017

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that...
Aug 30, 2016

RegeneRx to Present at Rodman & Renshaw 18th Annual Global Investment Conference

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Aug 29, 2016

RegeneRx Receives Notice of Intent to Grant Patent for the Treatment of Patients with Multiple Sclerosis in EU

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Aug 24, 2016

RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter

FDA Accepts Phase 3 Design Based on Results from Previous Phase 2b/3 Dry Eye Trial

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Aug 3, 2016

RegeneRx Receives Notice of Allowance for Key U.S. Patent That Expands and Extends Exclusivity of Company's Product Candidates

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jun 27, 2016

RegeneRx Announces $1.75 Million Private Placement

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jun 14, 2016

Thymosin Beta 4 Effective in Treatment of Heart Attack Patients

First Human Study Demonstrates Significant Clinical and Functional Improvements

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a...
Jun 1, 2016

RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China

RegeneRx Biopharmaceuticals, Inc. ("RegeneRx", OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings...
May 27, 2016

RegeneRx Comments on Valuation

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, made the following comments today on its stock price:
May 17, 2016

RegeneRx Releases Letter to Stockholders

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today released the following letter to...
May 10, 2016

Rodman & Renshaw Updates Analyst Report on RegeneRx Biopharmaceuticals, Inc. with Buy Rating

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that Rodman & Renshaw, a unit of...
May 6, 2016

RGN-259 Confirms Efficacy in Signs and Symptoms of Dry Eye

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced...
Apr 28, 2016

RegeneRx and ReGenTree Expand License for Dry Eye

Data from dry eye trial expected to be released the week of May 2nd

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that it has expanded its license to ReGenTree, LLC for RGN-259 in North American from solely the U.S....
Apr 6, 2016

RegeneRx to Receive EU Patent for Use of Tb4 in Preventing And Treating Damage Associated with Reperfusion Injury

Patent Will Enhance Coverage for Systemic Use of RGN-352

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Mar 14, 2016

Rodman & Renshaw Initiates Coverage of RegeneRx Biopharmaceuticals, Inc. with Buy Rating

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that Rodman & Renshaw, a unit of...
Feb 1, 2016

RegeneRx Meeting with Institutional Investors and Analysts At BIO CEO Conference

Results from Phase 2b/3 Dry Eye Trial Expected in Early 2016

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jan 29, 2016

RegeneRx Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jan 28, 2016

RegeneRx U.S. Joint Venture, ReGenTree, Launches Web Site

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jan 27, 2016

RegeneRx's TB4 Shown to Promote Regeneration and Repair of Damaged Central Nervous System Cells

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the...
Dec 23, 2015

RegeneRx Joint Venture Posts Results of Severe Dry Eye Trial On ClinicalTrials.gov

Phase 2 Trial Meets Key Efficacy Objectives

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Dec 4, 2015

RegeneRx Receives Chinese Patent for Key TB4 Peptide Fragment

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Oct 28, 2015

RegeneRx Analyst Report Update Issued by SeeThruEquity, LLC

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that SeeThruEquity, LLC's research...
Oct 23, 2015

RegeneRx Updates on Asian Ophthalmic Clinical Trials

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today is providing...
Oct 21, 2015

RegeneRx Updates on U.S. Ophthalmic Clinical Trials

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today is providing...
Oct 20, 2015

RegeneRx's TB4 Shown to Significantly Limit Brain Damage After Stroke by Upregulating microRNA-200a

TB4 Increases Stem Cell Survival and Differentiation

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a...
Sep 30, 2015

RegeneRx Receives $500,000 Milestone Payment With Enrollment of First Patient in U.S. Phase 2b/3 Dry Eye Trial

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Sep 21, 2015

RegeneRx Announces First Patient Enrolled in Phase 3 U.S. Neurotrophic Keratopathy (NK) Clinical Trial with RGN-259

Data Expected in Early 2016

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that...
Sep 16, 2015

RegeneRx Announces First Patients Enrolled in Phase 2b/3 U.S. Dry Eye Clinical Trial with RGN-259

Data Expected in Early 2016

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, announced today that...
Sep 2, 2015

RegeneRx to Present at Rodman & Renshaw Global Investment Conference

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Aug 12, 2015

New Publication Elaborates on TB4's Effects on Dry Eye Syndrome and Other Potential Ophthalmic Disorders

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a...
Aug 6, 2015

RegeneRx Provides Update on Clinical Trials in U.S., Korea and China

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today provided an...
Jul 22, 2015

RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jul 17, 2015

RegeneRx Korean Licensee Receives Government Approval to Conduct Phase 2b/3 Clinical Trial in Patients with Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, was informed today...
Jul 14, 2015

U.S. PTO Issues Notice of Allowance for Patent using TB4 for Improving Neurological Outcomes After Injury and Neurodegenerative Disease

Intellectual Property Developed at Henry Ford Hospital System and Licensed to RegeneRx Biopharmaceuticals

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jun 2, 2015

Clinical Trial Demonstrates Elevated Thymosin Beta 4 Plasma Levels are Associated with Improvement of Symptoms After Stem Cell Therapy in Patients with Ischemic Heart Failure

Functional Improvement Six Months After Heart Attack Correlated with Higher TB4 Levels

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced a peer-reviewed publication of the results of a recent cardiac stem cell clinical trial that...
May 22, 2015

RegeneRx to Present at 2 Investor Conferences

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that J.J. Finkelstein, chief...
May 22, 2015

Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology

Statistically Significant Findings Identify Key Efficacy Targets for Phase IIb/III Clinical Trial with RGN-259

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced a peer-reviewed publication of the results of the Company's 72-patient, placebo-controlled Phase II...
May 8, 2015

Researchers Report that Long-Term Administration of Thymosin B4 in a Diabetic Animal Model Prevents Progression of Peripheral Neuropathy and Restores Sciatic Nerve Function

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that independent researchers have...
May 4, 2015

Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that an independent team of researchers from South Korea have reported that Thymosin B4 (TB4) plays an...
Apr 23, 2015

RegeneRx Receives Notice of Allowance For U.S. Patent For Healing and Reversing Heart and Coronary Vessel Damage After A Heart Attack with TB4

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent...
Apr 16, 2015

RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced its U.S. joint venture with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. to conduct a phase 3...
Apr 1, 2015

RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that a new medical paper has been published describing the positive effects of Thymosin beta 4 (TB4)...
Apr 1, 2015

RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that a new medical paper has been published describing the positive effects of Thymosin beta 4 (TB4)...
Mar 26, 2015

RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx") today announced that it has received a patent acceptance notice from the Israeli patent office with claims for...
Mar 25, 2015

RegeneRx Receives Initial Payment for RGN-259 U.S. License to ReGenTree Joint Venture

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx" or the "Company") has received an initial payment of $500,000 from ReGenTree, LLC, its U.S. joint venture with G-TreeBNT Co. Ltd.,...
Mar 9, 2015

RegeneRx Joint Venture Partner Receives $7.28 million USD From Korean Government and Venture Fund for U.S. Development of RGN-259/GBT-201

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx") has been notified that its joint venture partner and licensee, G-treeBNT Co. Ltd., will receive $7.28 million USD to expand...
Mar 3, 2015

Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases

Oligodendrogenesis and Myelination are common links by which TB4 promotes recovery

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") In an editorial in the scientific journal, Expert Opinion on Biological Therapy, Dr. Michael Chopp and his colleague,...
Feb 25, 2015

RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that it has received an Israeli patent with claims for preventing, inhibiting or reducing heart tissue...
Feb 19, 2015

RegeneRx Updates Website

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") updated its website to reflect recent commercial transactions and information related to development of its clinical...
Feb 17, 2015

RegeneRx Releases Letter to Shareholders

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today released the following letter to shareholders: Dear Shareholder: Having just completed a very important...
Jan 28, 2015

RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that it has entered into agreements with G-treeBNT Co. Ltd., to develop RGN-259 for dry eye syndrome...
Dec 29, 2014

RegeneRx Partner Submits Phase IIB/III IND to Korean Health Authority for RGN-259 for the Treatment of Dry Eye Syndrome

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx") announced that its strategic partner, G-treeBNT Co. Ltd., has filed an IND with the Korean Ministry of Food and Drug Safety (MFDS) for...
Nov 25, 2014

Researchers Report Thymosin Beta 4 is Cardioprotective in Pulmonary Hypertension/Heart Failure Model

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today reported new published data demonstrating that Thymosin beta 4 (TB4) can be used effectively to prevent or...
Nov 6, 2014

RegeneRx Announces Management Changes

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx") today announced that the Company has retained Alan Klein, MBA, on a part-time basis as Chief Business Officer (CBO)...
Nov 3, 2014

U.S. Patent Office Significantly Extends the Term of Three RegeneRx Patents

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx") today announced that the U.S. Patent and Trademark Office (USPTO) has notified the Company that it is extending the...
Oct 24, 2014

Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model

Findings Have Important Implications in the Treatment of Central Nervous System Diseases and Injury

RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") today reported on data presented at the Fourth International Symposium on Thymosins in Health and Disease in Rome,...
Oct 23, 2014

Dr. Michael Chopp Reports on Successful Remodeling of the Central and Peripheral Nervous Systems after Injury/Disease Using Thymosin Beta 4

RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") today reported on data presented by Dr. Michael Chopp at the Fourth International Symposium on Thymosins in Health and...
Oct 20, 2014

RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy

RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting may begin Phase 3 to evaluate...
Sep 30, 2014

RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging

RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it has received a Canadian Patent for Inhibition or Reversal of Skin Aging by Actin-Sequestering...
Sep 3, 2014

RegeneRx Receives $1 Million Pursuant to Product License and Stock Purchase Agreement

RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it received a payment of $1 million, representing the last tranche of a $2.5 million product...

Show per page